RC
Therapeutic Areas
Aurinia Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LUPKYNIS (voclosporin) | Lupus Nephritis | Approved |
| Aritinercept | Autoimmune Diseases | Discovery/Preclinical |
| Voclosporin | Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 |
Leadership Team at Aurinia Pharmaceuticals
KT
Kevin Tang
Chair of the Board and Chief Executive Officer
MH
Michael Hearne
Chief Financial Officer
SK
Stew Kroll
Chief Development Officer
JB
Jeffrey Bailey
Board Director
KG
Kathy Goetz
Board Director
CJ
Craig Johnson
Board Director